Beginning 1 de janeiro, 2022, the below list of drugs will require step therapy for Medicare members as part of medical drug review. There are also nine drugs that as of 1 de janeiro, 2022 will require prior authorization (PA) for the first time but will also have step therapy.
- Will require documentation of trial and failure of Kanjinti and Trazimera (PA already exists):
J9355 Herceptin
- Will require documentation of trial and failure of Truxima and Riabni (PA already exists):
J9312 Rituxan
Q5119 Ruxience
J9310 Rituximab
- Will require documentation of trial and failure of Avastin, Mvasi, and Zirabev (PA already exists):
J0178 Eyelea
J0179 Beovu
J2778 Lucentis
- Will require documentation of trial and failure of Zoledronic acid (PA already exists):
J0897 Xgeva
J0897 Prolia
- Will require documentation of trial and failure of Euflexxa, Orthovisc, and Durolane (PA required as of 1 de janeiro, 2022):
J7327 Monvisc
J7325 Synvisc
J7321 Hyalgan
J7328 Gelsyn
J7321 Supartz
J7320 Genvisc
J7329 Trvisc
J7322 Hymovis
J7332 Triluron
- Will require documentation of trial and failure of Remicade, Inflectra, and Avsola (PA already exists):
Q5104 Renflexis
- Will require documentation of trial and failure of Neulasta and Udenyca (PA already exists):
Q5122 Byvepria
Q5108 Fulphila
Q5120 Ziextenzo
- Will require documentation of trial and failure of Sandostatin LAR (PA already exists):
J1930 Somatuline Depot